(-)-Blebbistatin: Benchmark Cell-Permeable Non-Muscle Myosin II Inhibitor

Executive Summary. (-)-Blebbistatin (CAS 856925-71-8) is a potent, reversible, and highly selective inhibitor of non-muscle myosin II (NM II), with an IC₅₀ range of 0.5–5.0 μM for NM II and minimal activity against myosin isoforms I, V, and X (APExBIO; Wu et al., 2023). It is cell-permeable, insoluble in water or ethanol, but dissolves in DMSO at ≥14.62 mg/mL, facilitating in vitro and in vivo use (APExBIO). Applications span cytoskeletal dynamics, cardiac contractility, and developmental biology, including MYH9-related disease and tumor mechanics studies (Pamidronatedisodium.com). Its use in zebrafish models demonstrates dose-dependent cardia bifida induction, underlining specificity for actomyosin contractility pathways. Storage at -20°C as a solid and prompt solution use preserves compound integrity and reproducibility.

Biological Rationale

Non-muscle myosin II (NM II) is a fundamental actin-dependent motor protein responsible for generating contractile forces, regulating cell adhesion, migration, and tissue morphogenesis. NM II activity underpins cytoskeletal organization and mechanotransduction in both normal physiology and disease, including cancer cell invasion and cardiac tissue remodeling (Wu et al., 2023). Selective pharmacological inhibition of NM II enables causal studies of actomyosin contractility pathways without global disruption of other myosin functions. (-)-Blebbistatin has become the gold standard for NM II-specific inhibition, displacing less selective compounds and genetic approaches for many applications (see comparison).

Mechanism of Action of (-)-Blebbistatin

(-)-Blebbistatin binds the myosin-ADP-phosphate complex, stabilizing it and slowing phosphate release. This suppresses Mg-ATPase activity and inhibits contractile function mediated by actomyosin interactions (APExBIO). The inhibition is reversible and highly selective for NM II, with minimal effects on non-target myosin isoforms. IC₅₀ values for NM II range from 0.5 to 5.0 μM, while activity against smooth muscle myosin II is substantially weaker (IC₅₀ ~80 μM) (Further mechanistic insight). The compound is cell-permeable, facilitating both live-cell and tissue-level studies. Solubility is optimal in DMSO, with recommended working solutions prepared at concentrations up to 14.62 mg/mL. Solutions should be used promptly to minimize photo- and chemical degradation, and storage as a solid at -20°C is advised.

Evidence & Benchmarks

• (-)-Blebbistatin inhibits NM II with an IC₅₀ between 0.5–5.0 μM under standard in vitro conditions (APExBIO).
• The compound shows negligible inhibition of myosin I, V, X, and minimal effect on smooth muscle myosin II at <80 μM (Mechanistic review).
• In zebrafish embryos, (-)-Blebbistatin induces dose-dependent cardia bifida, confirming specificity for actomyosin contractility in vivo (Wu et al., 2023).
• Cardiac muscle contractility and intercellular calcium waves are modulated by (-)-Blebbistatin, supporting its use in heart physiology studies (APExBIO translational guidance).
• Stock solutions (DMSO, 14.62 mg/mL) are stable for several months at -20°C; precipitation and degradation increase above this temperature (APExBIO).

Applications, Limits & Misconceptions

Applications.

• Cytoskeletal Dynamics Research: Enables rapid, reversible inhibition of actin-myosin interactions in live cells or tissues.
• Cell Adhesion & Migration Studies: Dissects NM II-dependent cell motility and mechanotransduction (selectivity review).
• Cardiac Muscle Contractility Modulation: Used to parse actomyosin contributions to heart rhythm, distinct from direct HCN channel effects (Wu et al., 2023).
• MYH9-Related Disease Modeling: Facilitates investigation of MYH9 mutation phenotypes and their mechanistic underpinnings (disease modeling review).
• Cancer Progression & Tumor Mechanics: Allows interrogation of actomyosin contractility in cancer cell invasion and metastasis.

Common Pitfalls or Misconceptions

• (-)-Blebbistatin does NOT significantly inhibit myosin I, V, or X at research-relevant concentrations.
• It is NOT water- or ethanol-soluble; DMSO is required for stock solutions (APExBIO).
• Blebbistatin is light-sensitive and prone to photodegradation; always handle under low-light conditions.
• Reversibility does NOT imply immediate washout; functional recovery may depend on cell type and wash protocol.
• It does NOT block HCN channels or directly affect cardiac pacemaker ion currents (Wu et al., 2023).

This article extends existing reviews by integrating recent findings on tissue-specific contractility and benchmarking APExBIO's B1387 formulation against alternative NM II inhibitors, clarifying distinctions from prior selectivity analyses.

Workflow Integration & Parameters

Researchers should prepare stock solutions of (-)-Blebbistatin in anhydrous DMSO at concentrations up to 14.62 mg/mL. Solutions must be stored at -20°C and protected from light. Warm solutions gently and use brief sonication if precipitation occurs. For cell-based assays, dilute stock into culture medium immediately before use, ensuring final DMSO concentrations do not exceed 0.1–0.5% (v/v) to avoid solvent toxicity. Typical working concentrations range from 1–10 μM, depending on cell type and endpoint. For animal studies, dosing regimens and routes should be empirically optimized, starting with published models (e.g., zebrafish embryos, cardiac tissue). All experiments should include appropriate DMSO and untreated controls (APExBIO). For extended protocols and translational considerations, see APExBIO's guidance article, which offers strategic deployment scenarios across disease models. This complements classic actomyosin inhibition reviews by detailing workflow bottlenecks and storage best practices.

Conclusion & Outlook

(-)-Blebbistatin remains the reference small molecule for selective NM II inhibition, enabling reproducible and interpretable studies of cell adhesion, migration, cardiac contractility, and developmental biology. Its physicochemical profile, selectivity, and reversibility distinguish it from alternatives and genetic approaches. Ongoing work, including integration with CRISPR models and advanced cardiac physiology, continues to expand its utility. For validated protocols and updates, refer to the APExBIO product page and the latest peer-reviewed literature (Wu et al., 2023).